AKTX vs ZBAO Comparison

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Zhibao Technology Inc is a insurance technology company engaged in providing digital insurance brokerage services in China. 2B2C digital embedded insurance is their business model which is pioneered in China. It provides customized digital insurance solutions for B-side channels (covering a wide range of industries and organizations, including but not limited to Internet platforms, large and medium-sized enterprises, and government agencies, etc.), embedding them into the channel's existing business matrix, and providing the channel with Provide digital insurance brokerage services to C-end customers.